Effect of Crocin on non-alcoholic fatty liver disease

Evaluation of the effect of Crocin on the serum levels of liver enzymes and Lipid Profile in patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180513039634N1

Enrollment

Registered

2018-06-13

Start date

2018-05-26

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: receiving one tablet containing 15 mg of Crocin (Samisaz Pharmaceutical Co.) daily with meal for 8 weaks. Intervention 2: Control group: receiving one tablet placeb

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: > 18 years old Patient with NAFLD (according to ultrasonography and high level of AST and ALT)

Exclusion criteria

Exclusion criteria: Viral and autoimmune hepatitis Metabolic liver disease, alcohol and drug consumption Pharmacotherapy for NAFLD

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Enzymatic photometery.;AST. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Enzymatic photometery.;TC, TG, LDL, HDL. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Enzymatic photometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbazar Parsi

Ahvaz University of Medical Sciences

b_ghorbanzadeh82@yahoo.com+98 61 3391 3635

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026